COMPARISON OF EFFICACY AND SAFETY OF NARROWBAND UVB WITH 0.1% TACROLIMUS VS NARROWBAND UVB WITH 0.005% CALCIPOTRIOL IN TREATMENT OF VITILIGO

Launched by DR AYESHA WAHID · Mar 11, 2025

Keywords

ClinConnect Summary

This clinical trial is comparing two different treatments for vitiligo, a skin condition that causes patches of skin to lose their color. The study is looking at the effectiveness and safety of using a specific type of light therapy called narrowband UVB combined with either tacrolimus (a topical ointment) or calcipotriol (a vitamin D derivative). Researchers want to see which combination works better for people with stable vitiligo that affects less than 20% of their skin.

To participate in this trial, individuals must be between 15 and 70 years old, have localized vitiligo that has been stable for at least three months, and meet certain health criteria. Unfortunately, pregnant or breastfeeding women, those with certain skin conditions or a history of allergies to the treatments, and individuals who have received other vitiligo treatments recently are not eligible. Participants can expect to receive the assigned treatment and be monitored for its effects on their skin over the course of the study. This trial has not started recruiting participants yet, so there will be more information available as it begins.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • - Localized vitiligo Age 15 to 70years Body surface upto 20% Stable more than 3 months
• Exclusion Criteria:
• • • Pregnant or lactating female patients.
• • Skin malignancy or any other malignant skin condition.
• • Photo induced or photo aggravated dermatosis like (SLE, photodermatitis, rosacea, psoriasis, pemphigus vulgaris) along with vitiligo.
• • Prior history of allergy to tacrolimus or calcipotriol.
• • Other form of treatment for vitiligo within at least 1 month.